Commentary

Ketamine formulation study is ‘groundbreaking’

Publish date: April 24, 2018

 

References

1. Biol Psychiatry. 2016 Sep 15;80(6):424-31.

2. JAMA Psychiatry. 2018 Feb 1;75(2):139-48.

3. Am J Psychiatry. 2018 Apr 16. doi: 10.1176/appi.ajp.2018.17060720.

4. Am J Psychiatry. 2018 Apr 1;175(4]):327-35.

5. Psychol Med. 2015 Dec;45(16):3571-80.

6. Am J Psychiatry. 2018 Feb 1;175(2):150-8.

7. Am J Psychiatry. 2016 Aug 1;173(8):816-26.

Pages

Recommended Reading

Consanguineous parentage raises risk of mood disorders, psychoses in offspring
MDedge Family Medicine
Rosacea tied to physical and psychological comorbidities
MDedge Family Medicine
Eating disorders put teens at risk for depression, bullying
MDedge Family Medicine
Anxiety, depression prevalent in children with comorbid autism and ADHD
MDedge Family Medicine
Esketamine nasal spray brings fast relief of depressive symptoms
MDedge Family Medicine
Change in approach advised for treatment-resistant depression
MDedge Family Medicine
Focus on early maladaptive schemas can reduce PTSD burden
MDedge Family Medicine
Suicide prevention, NRA team up for safer gun storage
MDedge Family Medicine
Fetal exposure to depression: How does ‘dose’ figure in?
MDedge Family Medicine
Suicide on the minds of many Utah teens
MDedge Family Medicine